Claims for Patent: 10,548,889

Summary for Patent: 10,548,889

Title:	Compositions of CXCR4 inhibitors and methods of preparation and use
Abstract:	The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
Inventor(s):	Brands Karel Marie Joseph
Assignee:	X4 PHARMACEUTICALS, INC.
Application Number:	US16215963
Patent Claims:	2. The X4P-001 composition of claim 1 , wherein the X4P-001 composition comprises each of I-2 claim 1 , I-3 claim 1 , I-5 claim 1 , I-6 claim 1 , and I-7; or a pharmaceutically acceptable salt thereof.4. The X4P-001 composition of claim 1 , wherein the amount of I-2 claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , is from about 0.01 to about 0.2% w/w of the X4P-001 composition.5. The X4P-001 composition of claim 4 , wherein the amount of I-3 claim 4 , or a pharmaceutically acceptable salt thereof claim 4 , is from about 0.01 to about 0.2% w/w of the X4P-001 composition.6. The X4P-001 composition of claim 5 , wherein the amount of I-5 claim 5 , or a pharmaceutically acceptable salt thereof claim 5 , is from about 0.01 to about 0.2% w/w of the X4P-001 composition.7. The X4P-001 composition of claim 6 , wherein the amount of I-6 claim 6 , or a pharmaceutically acceptable salt thereof claim 6 , is from about 0.01 to about 0.2% w/w of the X4P-001 composition.8. The X4P-001 composition of claim 7 , wherein the amount of I-7 claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , is from about 0.01 to about 0.2% w/w of the X4P-001 composition.9. The X4P-001 composition of claim 3 , wherein the amount of I-1 claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , is from about 0.02 to about 0.5% w/w of the X4P-001 composition.10. The X4P-001 composition of claim 1 , wherein the composition comprises at least two compounds selected from:I-2, or a pharmaceutically acceptable salt thereof,I-3, or a pharmaceutically acceptable salt thereof,I-5, or a pharmaceutically acceptable salt thereof,I-6, or a pharmaceutically acceptable salt thereof, orI-7, or a pharmaceutically acceptable salt thereof.11. The X4P-001 composition of claim 1 , wherein the composition comprises at least three compounds selected from:I-2, or a pharmaceutically acceptable salt thereof,I-3, or a pharmaceutically acceptable salt thereof,I-5, or a pharmaceutically acceptable salt thereof,I-6, or a pharmaceutically acceptable salt thereof, orI-7, or a pharmaceutically acceptable salt thereof.12. The X4P-001 composition of claim 1 , wherein the composition comprises at least four compounds selected from:I-2, or a pharmaceutically acceptable salt thereof,I-3, or a pharmaceutically acceptable salt thereof,I-5, or a pharmaceutically acceptable salt thereof,I-6, or a pharmaceutically acceptable salt thereof, orI-7, or a pharmaceutically acceptable salt thereof.